Recent advances in nanoantibiotics against multidrug-resistant bacteria,Nanoscale Advances

当前位置： X-MOL 学术 › Nanoscale Adv. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Recent advances in nanoantibiotics against multidrug-resistant bacteria
Nanoscale Advances ( IF 4.6 ) Pub Date : 2023-10-05 , DOI: 10.1039/d3na00530e
Mulan Li ₁ , Ying Liu ₂ , Youhuan Gong ₁ , Xiaojie Yan ₁ , Le Wang ₁ , Wenfu Zheng _{3,

4,

5} , Hao Ai ₂ , Yuliang Zhao _{3,

4,

6}

Affiliation

Multidrug-resistant (MDR) bacteria-caused infections have been a major threat to human health. The abuse of conventional antibiotics accelerates the generation of MDR bacteria and makes the situation worse. The emergence of nanomaterials holds great promise for solving this tricky problem due to their multiple antibacterial mechanisms, tunable antibacterial spectra, and low probabilities of inducing drug resistance. In this review, we summarize the mechanism of the generation of drug resistance, and introduce the recently developed nanomaterials for dealing with MDR bacteria via various antibacterial mechanisms. Considering that biosafety and mass production are the major bottlenecks hurdling the commercialization of nanoantibiotics, we introduce the related development in these two aspects. We discuss urgent challenges in this field and future perspectives to promote the development and translation of nanoantibiotics as alternatives against MDR pathogens to traditional antibiotics-based approaches.

中文翻译：

纳米抗生素对抗多重耐药菌的最新进展

多重耐药（MDR）细菌引起的感染一直是对人类健康的主要威胁。传统抗生素的滥用会加速耐多药细菌的产生，使情况变得更糟。纳米材料的出现为解决这一棘手问题带来了巨大希望，因为它们具有多种抗菌机制、可调节的抗菌谱以及诱导耐药性的可能性较低。在这篇综述中，我们总结了耐药性产生的机制，并介绍了最近开发的通过各种抗菌机制来应对MDR细菌的纳米材料。鉴于生物安全和大规模生产是纳米抗生素商业化的主要瓶颈，我们介绍了这两方面的相关进展。我们讨论了该领域的紧迫挑战以及未来的前景，以促进纳米抗生素的开发和转化，作为传统抗生素方法的替代品来对抗 MDR 病原体。

更新日期：2023-10-05

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文